These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22011446)

  • 21. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution.
    Buerger H; Mommers EC; Littmann R; Simon R; Diallo R; Poremba C; Dockhorn-Dworniczak B; van Diest PJ; Boecker W
    J Pathol; 2001 Jun; 194(2):165-70. PubMed ID: 11400144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
    Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
    J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
    Gao FF; Dabbs DJ; Cooper KL; Bhargava R
    Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas.
    Taniyama K; Ishida K; Toda T; Motoshita J; Kuraoka K; Saito A; Tani Y; Uike T; Teramoto S; Koseki M
    Breast Cancer; 2008; 15(3):231-40. PubMed ID: 18264744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the cellular centrosome in fine-needle aspirations of the breast.
    Guo HQ; Gao M; Ma J; Xiao T; Zhao LL; Gao Y; Pan QJ
    Breast Cancer Res; 2007; 9(4):R48. PubMed ID: 17662154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
    Hanna W; Nofech-Mozes S; Kahn HJ
    Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization.
    Somiari SB; Shriver CD; He J; Parikh K; Jordan R; Hooke J; Hu H; Deyarmin B; Lubert S; Malicki L; Heckman C; Somiari RI
    Cancer Genet Cytogenet; 2004 Dec; 155(2):108-18. PubMed ID: 15571796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
    Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
    Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
    Gong Y; Sweet W; Duh YJ; Greenfield L; Tarco E; Trivedi S; Symmans WF; Isola J; Sneige N
    Am J Clin Pathol; 2009 Aug; 132(2):228-36. PubMed ID: 19605817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
    McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
    Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.
    Halilovic A; Verweij DI; Simons A; Stevens-Kroef MJPL; Vermeulen S; Elsink J; Tops BBJ; Otte-Höller I; van der Laak JAWM; van de Water C; Boelens OBA; Schlooz-Vries MS; Dijkstra JR; Nagtegaal ID; Tol J; van Cleef PHJ; Span PN; Bult P
    Sci Rep; 2019 Aug; 9(1):11679. PubMed ID: 31406196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
    Zhu X; Lu Y; Lu H; Yang W; Tu X; Cai X; Zhou X
    Hum Pathol; 2011 Oct; 42(10):1499-504. PubMed ID: 21676436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnosis of HER2 gene amplification in breast carcinoma].
    Couturier J; Vincent-Salomon A; Mathieu MC; Valent A; Bernheim A
    Pathol Biol (Paris); 2008 Sep; 56(6):375-9. PubMed ID: 18456424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [HER2 gene amplification assay: is CISH an alternative to FISH?].
    Denoux Y; Arnould L; Fiche M; Lannes B; Couturier J; Vincent-Salomon A; Penault-Llorca F; Antoine M; Balaton A; Baranzelli MC; Becette V; Bellocq JP; Bibeau F; Ettore F; Fridman V; Gnassia JP; Jacquemier J; MacGrogan G; Mathieu MC; Migeon C; Rigaud C; Roger P; Sigal-Zafrani B; Simony-Lafontaine J; Trassard M; Treilleux I; Verriele V; Voigt JJ;
    Ann Pathol; 2003 Dec; 23(6):617-22. PubMed ID: 15094603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
    Courjal F; Cuny M; Simony-Lafontaine J; Louason G; Speiser P; Zeillinger R; Rodriguez C; Theillet C
    Cancer Res; 1997 Oct; 57(19):4360-7. PubMed ID: 9331099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
    Jiang H; Bai X; Zhao T; Zhang C; Zhang X
    Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.